Protagonist Therapeutics, Inc.

NASDAQ:PTGX

Biotechnology

Healthcare
$127.16 +1.54%

+$1.72 today

Market cap
$8.30B
Beta
1.83
P/E (TTM)
-64.2
EPS (TTM)
-$1.76
52W Low $49.38High $114.00

Volume 0.43M

Average 0.72M

PTGX Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Protagonist Therapeutics, Inc.NASDAQ: PTGX

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation growth accelerates

Q2 FY2026 stock-based compensation of $14.04M rose 28.6% year over year, ahead of the +13.3% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 3.3% from the prior quarter. Over 3 fiscal years it compounded at +23.8% a year.

Context

  • Stock-based compensation amounted to 99.9% of revenue in FY2025, up 91.3 pp from a year earlier.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +28.6% holds above the trailing-twelve-month pace of +13.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$14.04M-3.3% QoQ
Last fiscal yearDec 2025
$45.97M+22.4% YoY
LTMJun 2026
$49.82M+13.3% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+28.6%——
1 year+22.4%——
3-year CAGR+23.8%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
45.97M USD
Year-over-year change
+22.4%
4-year CAGR
+29.4%

Stock-Based Compensation vs competitors

How PTGX compares with its peers on the latest reported figures

  • PTGX's LTM Jun 2026 stock-based compensation of $49.82M is the 4th largest of the 7 companies compared; the peer median is $45.71M.
  • Its year-over-year change of +13.3% is the 5th highest of 7, against a peer median of +30.1%.
  • Stock-based compensation amounts to 17.7% of revenue for PTGX, versus a peer median of 99.8%.
PTGX Competitors Peer median
Stock-Based Compensation for PTGX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMVTImmunovant, Inc.LTM Sep 2026$50.91M -7.8%+19.9%717.6%
IRONDisc Medicine, Inc.LTM Sep 2026$50.54M +76.5%+154.3%—
SYRESpyre Therapeutics, Inc.LTM Sep 2026$50.3M +35.9%+74.2%55.6%
PTGXProtagonist Therapeutics, Inc.LTM Jun 2026$49.82M +13.3%+23.8%17.7%
ANABAnaptysBio, Inc.LTM Mar 2026$41.12M +24.3%+9.7%17.7%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$12.05M -2.1%-6.3%144.0%
IMUXImmunic, Inc.LTM Mar 2026$11.29M +44.4%+3.8%—
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding PTGX) $45.71M+30.1%+14.8%99.8%

Competitors are the stored peer set for PTGX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(125.55M)(127.39M)(78.96M)275.19M(130.15M)
Depreciation & Amortization2.78M3.37M3.31M2.96M1.28M
Deferred Income Tax00000
Stock-Based Compensation16.4M24.2M29.29M37.55M45.97M
Change in Working Capital(3.31M)(7.77M)(19.51M)(122.61M)146.21M
Accounts Receivables(915K)4.24M(9.99M)(155M)164.88M
Inventory915K(4.24M)000
Accounts Payables(1.39M)2.05M(2.87M)842K3.72M
Other Working Capital(1.92M)(9.81M)(6.65M)31.55M(22.39M)
Other Non-Cash Items1.83M(549K)(4.38M)(8.94M)(5.64M)
Operating Cash Flow(107.87M)(108.14M)(70.24M)184.15M57.67M
Capital Expenditures(1.1M)(795K)(609K)(1.36M)(1.59M)
Acquisitions (Net)14.76M(91.47M)000
Purchases of Investments(286.59M)(214.87M)(191.05M)(621.7M)(546.59M)
Sales of Investments271.83M307.14M152.4M323.57M498.84M
Other Investing Activities(14.76M)91.47M000
Investing Cash Flow(15.86M)91.47M(39.26M)(299.48M)(49.33M)
Debt Repayment00000
Common Stock Issued123.83M14.55M132.1M26.45M23.34M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities6.09M4.29M38.38M(600K)(479K)
Financing Cash Flow129.92M18.84M170.48M25.85M22.86M
Effect of Forex Changes(126K)(90K)00(62K)
Net Change in Cash6.07M2.08M60.98M(89.48M)31.14M
Free Cash Flow(108.97M)(108.93M)(70.85M)182.8M56.08M

Protagonist Therapeutics, Inc.

NASDAQ:PTGX

Intrinsic Alpha fair value

Locked

Current Price

$127.16

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.